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Background: Hypertrophic cardiomyopathy (HCM) sometimes shows left ventricular (LV) systolic dysfunction associated with LV remodeling. 
Although sarcomere gene mutations were shown to play an important role in LV remodeling, few data exist regarding possible modifier genes 
including renin-angiotensin system (RAS). Therefore, we examined the relationship between three RAS polymorphisms such as angiotensin-converting 
enzyme insertion/deletion (ACE I/D), angiotensinogen M235T (AGT M235T) and angiotensin II type 1 receptor A/C1166 (AT1 A/C1166) and 
echocardiographic parameters in HCM caused by sarcomere gene mutations.
Methods: We studied 59 HCM patients with 4 disease-causing sarcomere gene mutations namely MYH7 (n=10), MYBPC3 (n=15), TNNT2 (n=9), 
and TNNI3 (n=25) including typical and end-stage HCM (30 males, age 50±15years, mean follow-up period 7.4±4.4 years). LV wall thickness, LV 
dimensions and fractional shortening (FS) were serially measured with echocardiography.
Results: HCM with ACE D allele (DD and DI, n=37) exhibited significantly lower FS than those with II genotype (n=22) (32±12% vs 40±5.9%, 
p<0.01) at initial evaluation, as well as at last evaluation (31±12% vs 37±9.4% p<0.05). Under these conditions, AGT M235T and AT1 A/C1166 
polymorphisms were not associated with FS. At initial evaluation frequency of systolic dysfunction (FS<25%) was significantly higher in D allele 
(n=10, 27%) than II genotype (n=1, 4.5%) (p<0.05). Although at last evaluation frequency of systolic dysfunction was not different between two 
groups (p=0.10), interestingly, D allele with systolic dysfunction showed tendency to develop LV dilatation during follow-up period.
Conclusion: These results demonstrate that ACE D allele can influence the development of LV systolic dysfunction and subsequently transition 
to dilated phase of HCM in genotyped HCM. We suggest that, in addition to screening for disease-causing gene mutations, detection of ACE I/D 
polymorphisms may contribute to further risk stratification in HCM mutation carriers.
